ObsEva SA (OBSV)
Stock Price:
$1.89 USD
-0.16 (-7.80%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
105.68M |
| Revenue (ttm) |
18,000 |
| Net Income (ttm) |
-108.79M |
| Shares Out |
55.92M |
| EPS (ttm) |
-1.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$1.89 |
| Previous Close |
$2.05 |
| Change ($) |
-0.16 |
| Change (%) |
-7.80% |
| Day's Open |
2.02 |
| Day's Range |
1.86 - 2.02 |
| Day's Volume |
1,169,452 |
| 52-Week Range |
1.63 - 8.50 |
More Stats
| Market Cap |
105.68M |
| Enterprise Value |
63.39M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.92M |
| Float |
34.75M |
| EPS (basic) |
-2.49 |
| EPS (diluted) |
-1.95 |
| FCF / Share |
-1.99 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.29M |
| Short Ratio |
3.02 |
| Short % of Float |
3.72% |
| Beta |
0.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5,871.25 |
| PB Ratio |
4.86 |
| Revenue |
18,000 |
| Operating Income |
-107.11M |
| Net Income |
-108.79M |
| Free Cash Flow |
-90.66M |
| Net Cash |
42.29M |
| Net Cash / Share |
0.76 |
| Gross Margin |
88.89% |
| Operating Margin |
-595,061.11% |
| Profit Margin |
n/a |
| FCF Margin |
-503,650.00% |
| ROA |
-51.47% |
| ROE |
-149.83% |
| ROIC |
-3,640.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (7)
| Buy |
5 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.43*
(557.67% upside)
Low
4.00
Current: $1.89
High
30.00
Target: 12.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -107 | -77.17 | -67.48 | -30.16 | -19.85 | -12.92 |
| Net Income | -109 | -76.72 | -66.93 | -30.20 | -19.87 | -12.81 |
| Shares Outstanding | 45.48 | 37.13 | 23.18 | 22.36 | 22.36 | - |
| Earnings Per Share | -2.49 | -1.91 | -2.25 | -1.40 | -1.87 | -1.41 |
| Operating Cash Flow | -90.61 | -63.94 | -55.72 | -28.59 | -13.91 | -12.12 |
| Capital Expenditures | -0.05 | -0.19 | -0.19 | -0.05 | -0.05 | -0.10 |
| Free Cash Flow | -90.66 | -64.13 | -55.90 | -28.63 | -13.96 | -12.23 |
| Cash & Equivalents | 69.37 | 139 | 111 | 25.51 | 54.28 | 4.01 |
| Total Debt | 27.08 | - | - | - | - | - |
| Net Cash / Debt | 42.29 | 139 | 111 | 25.51 | 54.28 | 4.01 |
| Assets | 104 | 167 | 135 | 45.53 | 71.59 | 9.28 |
| Liabilities | 54.99 | 20.52 | 12.58 | 9.48 | 6.92 | 3.29 |
| Book Value | 48.96 | 147 | 123 | 36.04 | 64.68 | 5.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ObsEva SA |
| Country |
Switzerland |
| Employees |
53 |
| CEO |
Ernest Loumaye |
Stock Information
| Ticker Symbol |
OBSV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OBSV |
| IPO Date |
January 26, 2017 |
Description
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.